The anti-PD-1 therapy has been specifically recommended for use alongside platinum- and fluoropyrimidine-based chemotherapy to treat untreated locally advanced unresectable or metastatic human epidermal growth factor 2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a combined positive score (CPS) of one or more.
More than 6,500 new diagnoses of gastric cancer are made in the UK every year and adenocarcinomas, which develop from cells in the innermost lining of the stomach, account for the majority of cases…
